Is fenelidone a hormonal drug?

Finerenone is a non-steroidal selective aldosterone receptor antagonist (MRA) and is not a hormonal drug in the traditional sense. Its mechanism of action is similar to that of steroidal MRAs (such as spironolactone and eplerenone), but its structure and pharmacological properties are different, allowing it to show better safety and efficacy in the treatment of related diseases.

As a highly selective aldosterone receptor antagonist, fenelinone reduces sodium retention and edema by blocking the effects of aldosterone on the distal renal tubules and collecting ducts, while reducing cardiovascular and renal damage. Different from traditional steroidal MRAs (such as spironolactone), the chemical structure of fenelinone makes it more selective for mineralocorticoid receptors, reducing the impact on androgen and progesterone receptors, thereby reducing common adverse reactions of steroidal MRAs such as male breast development and female menstrual disorders.

The main clinical indications for fenelidone include patients with chronic kidney disease (CKD) combined with type 2 diabetes (T2DM). These patients often suffer from kidney damage and increased cardiovascular risk due to the excessive effects of aldosterone. Large-scale clinical trials (such as the FIDELIO-DKD study and the FIGARO-DKD study) have shown that fenelinone can effectively reduce the risk of renal function deterioration and cardiovascular adverse events in patients with diabetic nephropathy, providing a new treatment option for such patients.

Although fenelinone is not a hormonal drug, due to its influence on the aldosterone signaling pathway, blood potassium levels still need to be closely monitored when used, especially for patients with a high risk of hyperkalemia, such as patients with chronic kidney disease and takingRAAS inhibitors (such as ACEI, ARB). Therefore, in clinical application, doctors will adjust the dosage according to the patient's renal function and blood potassium level to minimize side effects while maintaining its advantages in cardiorenal protection.

Reference materials:https://www.kerendia.com/